Ceftolozane-Tazobactam Split-Fill Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmaceutical composition comprising ceftolozane and tazobactam experiences an increase in total ceftolozane related substance impurities over time, leading to decreased ceftolozane levels and potential instability, which affects the shelf-life and usability of unit dosage forms.
Innovation Solution
The compositions are manufactured by combining ceftolozane and tazobactam in a 'split-fill' or 'two-container' presentation, where they are initially stored separately and combined at the point of use, reducing the time for impurity formation and maintaining stability, or by co-lyophilizing them within a unit dosage form container, thereby extending the shelf-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If ceftolozane and tazobactam are combined in a single blended composition prior to filling into unit dosage form containers, then the manufacturing process is simplified and easier to produce, but the total amount of ceftolozane related substance impurities increases over time due to prolonged contact between the two components
Solution Approach 1:
The patent divides the composition into separate ceftolozane-containing compositions and tazobactam-containing compositions that are filled into unit dosage form containers separately. These separate compositions are then combined at the point of use by the healthcare provider, rather than being pre-blended. This segmentation prevents impurity formation during storage while maintaining manufacturing simplicity through standardized separate filling processes.
2Productivity
If ceftolozane and tazobactam are combined in a single blended composition prior to filling into unit dosage form containers, then production efficiency is improved, but the shelf-life of the unit dosage form is reduced due to increased impurity formation
Solution Approach 1:
The patent implements separate filling of ceftolozane and tazobactam into unit dosage form containers, eliminating pre-blending. This segmentation allows each component to be stored separately without impurity formation, thereby extending shelf-life while maintaining high productivity through efficient separate filling and point-of-use combination.
Solution Approach 2:
The patent performs preliminary separate filling and packaging of ceftolozane and tazobactam compositions into unit dosage form containers before their final combination. This preliminary action in separate containers prevents impurity formation during storage and extends shelf-life, while the combination at point of use maintains production efficiency.
3Reliability
If ceftolozane and tazobactam are stored separately and combined at the point of use, then the formation of ceftolozane related substance impurities is reduced, but the complexity of the manufacturing and distribution process increases
Solution Approach 1:
The patent segments the composition into separate ceftolozane-containing and tazobactam-containing unit dosage form containers. This segmentation reduces impurity formation and enhances stability, while the complexity is managed through standardized separate filling processes and clear combination instructions for healthcare providers at the point of use.
4Ease of operation
If ceftolozane and tazobactam are combined in a single blended composition, then the composition is easier to handle and administer, but the purity of the ceftolozane decreases over time due to chemical interaction
Solution Approach 1:
The patent segments the composition into separate containers that are combined at the point of use. This maintains purity by preventing chemical interactions during storage and manufacturing, while ease of operation is preserved through standardized combination procedures and clear labeling instructions for healthcare providers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the formation of ceftolozane related substances, maintaining the composition's stability and potency for a longer period, ensuring compliance with specifications and effective treatment.
Implementation Method 1
Pharmaceutical compositions comprising one or more drug substances can be prepared by lyophilization of a solution containing the drug substance(s). Lyophilization is a process of freeze-drying in which water is sublimed from a frozen solution of one or more solutes.
Data Source
AI summary
Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.